Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Quintrigen is developing p53, a targeted anti-cancer and tumor suppressor drug.
The company has identified a family of small peptides that can reeducate mutant p53 to do its job. In pre-clinical models, these peptides have been shown to reactivate a wide variety of different mutant p53 proteins by refolding the mutant p53 to its natural native conformation and restoring its potent wild-type functionality, including the capability to induce cancer cell death. The treatment is shown to be highly selective against cancer cells, sparing normal cells and tissues.
Quintrigen is a joint venture of the Weizmann institute in Israel and South Korean biotech Bioleaders.